Block listing Interim Review

AstraZeneca PLC

02 December 2024

 

2 December 2024 15:05 GMT

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 2 December 2024

Name of applicant:		ASTRAZENECA PLC
Name of scheme:		ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return:	From:	1 JUNE 2024	To:	30 NOVEMBER 2024
Balance of unallotted securities under scheme(s) from previous return:		4,090,043
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		60,887
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		4,029,156

Name of contact:	Hannah Tattersall
Telephone number of contact:	[phone]

AstraZeneca 

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END